Tectonic Therapeutic financials
$23.34−0.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$84.0M | -$58.0M |
| Net income | -$74.2M | -$58.0M |
| Net margin | — | — |
| Diluted EPS | $-4.05 | $-6.83 |
| EBITDA | -$82.7M | -$56.4M |
| Operating cash flow | -$60.1M | -$59.1M |
| Free cash flow | -$60.3M | -$59.2M |
| Diluted shares | 18.3M | 8.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $253.8M | $141.2M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $387.0K | $876.0K |
| Total assets | $261.0M | $152.9M |
| Total liabilities | $9.7M | $12.1M |
| Shareholders' equity | $251.3M | $140.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology